Decheng Capital

What is Decheng Capital?

Decheng Capital is an investment firm that specializes in providing capital and strategic support to early-stage life science companies with revolutionary technologies as well as growth-stage healthcare companies with strong market presence. Established in 2012 and headquartered in Shanghai, China, Decheng Capital operates with a focus on various industries such as Software, IT, Education, BioTech, Business Solutions, FinTech, Hardware, Logistics, Medical Devices, Aerospace, Life Science, and Oncology.

Their investment approach is characterized by a blend of expertise in Equity, with specialties in MBO/LBO, Turnaround, Recapitalization, Corporate Divestiture, and Early-stage investments. With a clear investment thesis that targets both early and growth stages within the healthcare sector, Decheng Capital manages assets with a value of $2.1 billion. Their investment size generally holds at around $58,060,000, both as a minimum and a maximum figure, demonstrating their commitment to substantial, strategic investments.

Decheng Capital's team of dedicated professionals combines complementary expertise to build highly successful companies on a global scale. Thanks to a historic opportunity presented by the rapid growth of the healthcare industry and breakthroughs in life science research, Decheng positions itself as a preferred partner for entrepreneurs, world-class scientists, and strategic partners.

As they aim to create value for their investors and entrepreneurial partners, Decheng has garnered support from prestigious limited partners worldwide. Their impact is highlighted by significant deals and company growth announcements in the life science and healthcare spaces, ensuring Decheng Capital's prominent role in shaping the future of these industries.

What they say:

We are a venture capital firm providing capital.

What we look for: We invest in early and growth stage life science companies.